Free Trial

Vera Therapeutics (NASDAQ:VERA) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS

Vera Therapeutics logo with Medical background

Vera Therapeutics (NASDAQ:VERA - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21), Briefing.com reports.

Vera Therapeutics Stock Performance

VERA traded down $0.95 during trading on Friday, hitting $48.09. 614,475 shares of the company traded hands, compared to its average volume of 914,612. The firm has a market cap of $2.64 billion, a P/E ratio of -21.76 and a beta of 1.03. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. The stock's fifty day moving average is $41.53 and its 200 day moving average is $39.17. Vera Therapeutics has a one year low of $10.79 and a one year high of $50.78.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 15,000 shares of the firm's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $48.03, for a total value of $720,450.00. Following the sale, the director now owns 131,553 shares of the company's stock, valued at $6,318,490.59. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Vera Therapeutics news, CEO Marshall Fordyce sold 19,375 shares of the business's stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $40.39, for a total value of $782,556.25. Following the completion of the sale, the chief executive officer now directly owns 307,972 shares of the company's stock, valued at $12,438,989.08. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Beth C. Seidenberg sold 15,000 shares of the firm's stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $48.03, for a total value of $720,450.00. Following the transaction, the director now directly owns 131,553 shares in the company, valued at $6,318,490.59. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,398 shares of company stock valued at $4,376,163 over the last three months. Company insiders own 21.70% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a report on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Wedbush increased their target price on Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a report on Friday. Scotiabank initiated coverage on Vera Therapeutics in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $60.00 price objective for the company. Finally, Evercore ISI upgraded Vera Therapeutics to a "strong-buy" rating in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $54.33.

Check Out Our Latest Stock Analysis on VERA

Vera Therapeutics Company Profile

(Get Free Report)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Further Reading

Earnings History for Vera Therapeutics (NASDAQ:VERA)

→ Trump won. Buy this coin now. (From Weiss Ratings) (Ad)

Should you invest $1,000 in Vera Therapeutics right now?

Before you consider Vera Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.

While Vera Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Star Bulk Carriers Stock 28% Upside: Can This Small Cap Deliver?

Star Bulk Carriers Stock 28% Upside: Can This Small Cap Deliver?

As global trade ramps up, especially with China's market expansion, could Star Bulk Carriers be your next big opportunity?

Related Videos

These 3 Small-Cap Stocks Could be the Hidden Gems of 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines